Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML

Blood (2024) 144 (Supplement 1): 4265.5.

https://doi.org/10.1182/blood-2024-208998

Published: 2024

Journal Articles

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated with Upregulation of HOX Genes: Trial in Progress

Ghayas C. Issa, Kuo-Kai Chin, James S. Blachly, Aziz Farhat, Lianchun Xiao, Jing Ning, Branko Cuglievan, Neerav Shukla, Koji Sasaki, Sanam Loghavi, Sheng Cai, Hagop M. Kantarjian, Eytan M. Stein

Blood (2024) 144 (Supplement 1): 5995.

https://doi.org/10.1182/blood-2024-203466

Published: 2024

Journal Articles

A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

Blood (2024) 144 (Supplement 1): 4265.2.

https://doi.org/10.1182/blood-2024-201582

Published: 2024

Journal Articles

Azacitidine, Venetoclax and Allogeneic NK Cells in Newly Diagnosed Acute Myeloid Leukemia (ADVENT-AML): An Investigator-Initiated Multicenter Phase Ib Trial

Abhishek Maiti, Muharrem Muftuoglu, James J. Ignatz-Hoover, Courtney D. DiNardo, Farhad Ravandi, Michael Andreeff, Lianchun Xiao, Xuelin Huang, Keyur P. Patel, Jason B Litten, Eliot Bourk, Stephanie Astrow, Hagop M. Kantarjian, Ben K. Tomlinson, Naval Daver, David Wald

Blood (2023) 142 (Supplement 1): 4863.

https://doi.org/10.1182/blood-2023-182885

Published: 2023

Journal Articles

Characteristics and Outcomes of Adult Patients with Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Single-Center, Prospective Analysis

Blood (2021) 138 (Supplement 1): 1213.

https://doi.org/10.1182/blood-2021-152897

Published: 2021

Journal Articles

Improved Survival for MDS/CMML Patients Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC Alone Vs. DAC +/- Carboplatin or ATO

Patricia L. Kropf, MD, Raji Shameem, MD, Philip A. Pancari, MD, Henry Fung, MD, Lianchun Xiao, PhD, Xuelin Huang, PhD, Woonbok Chung, PhD, Hagop M. Kantarjian, MD, Jean-Pierre J. Issa, MD

Blood (2016) 128 (22): 3170.

https://doi.org/10.1182/blood.V128.22.3170.3170

Published: 2016

Journal Articles

Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML)

Naval Daver, MD, Sreyashi Basu, PhD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Jing Ning, PhD, Lianchun Xiao, PhD, Lopez Juliana, MD, Steven M. Kornblau, MD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Wilmer Flores, Carlos E Bueso-Ramos, MD PhD, Narmeen Somani, Jorge Blando, DVM, James Allison, PhD, Hagop M. Kantarjian, MD, Padmanee Sharma, MD PhD

Blood (2016) 128 (22): 2900.

https://doi.org/10.1182/blood.V128.22.2900.2900

Published: 2016

Journal Articles

Superior Response Rates for Patients with Myeloid Malignancies Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC +/- Carboplatin or ATO

Patricia L. Kropf, MD, Philip A. Pancari, MD, Henry Fung, Hagop M. Kantarjian, MD, Lianchun Xiao, Huang Xuelin, Jean-Pierre Issa, MD

Blood (2015) 126 (23): 3775.

https://doi.org/10.1182/blood.V126.23.3775.3775

Published: 2015

Journal Articles

A Phase I/II Study Of Hyper-CVAD Plus Everolimus In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Naval Daver, MD, Hagop M. Kantarjian, MD, Deborah A. Thomas, MD, Michael E. Rytting, MD, Farhad Ravandi, MD, Nitin Jain, MD, Jorge E. Cortes, MD, Rebecca Garris, BSc, Mary Ann Richie, RN, Marina Konopleva, MD, PhD, Hongbo Hu, PHD, Jitesh Kawedia, PHD, BS, Kirk Culotta Pharmd, BS, Susan O'Brien, MD, Jordan Basnett, Lianchun Xiao, Xuelin Haung, Linda J. Bendall, BSc, PhD

Blood (2013) 122 (21): 3916.

https://doi.org/10.1182/blood.V122.21.3916.3916

Published: 2013

Journal Articles

Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure

Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Lianchun Xiao, Al Ali Najla, Asmita Mishra, MD, Eric Padron, MD, Jeffrey E Lancet, MD, Jeffery Bryan, Hillary Prescott, David P. Steensma, MD, Mikkael A. Sekeres, MD, MS, Gail J. Roboz, MD, Alan List, MD, Hagop M Kantarjian, MD, Rami S Komrokji, MD

Blood (2013) 122 (21): 388.

https://doi.org/10.1182/blood.V122.21.388.388

Published: 2013

Journal Articles

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia

Blood (2013) 122 (11): 1891–1899.

https://doi.org/10.1182/blood-2013-01-478222

Published: 2013

Includes: Supplemental data

Journal Articles

Serum CCL3 and CCL4 Levels Function As Novel Prognostic Markers in Diffuse Large B Cell Lymphoma.

Koichi Takahashi, MD, Mariela Sivina, PhD, Yasuhiro Oki, MD, Luis E Fayad, MD, Sattva S. Neelapu, MD, Larry W. Kwak, MD, PhD, Lianchun Xiao, Xuelin Huang, PhD, Kai Fu, MD, PhD, Wing Chung Chan, MD, Julie M Vose, MD, MBA, Hagop M. Kantarjian, MD, Michael Keating, MD, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 2709.

https://doi.org/10.1182/blood.V120.21.2709.2709

Published: 2012

Journal Articles

Coagulation Profile As Prognostic Indicator in Acute Myeloid Leukemia,

Francisca C. Gushiken, MD, Yen Dai Vo, Lianchun Xiao, Tapan Kadia, Jorge E. Cortes, Naveen Pemmaraju, MD, Sherry Pierce, RN, BS, Hagop M. Kantarjian, MD, Gautam Borthakur

Blood (2011) 118 (21): 3593.

https://doi.org/10.1182/blood.V118.21.3593.3593

Published: 2011

Journal Articles

CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia

Mariela Sivina, Elena Hartmann, Thomas J. Kipps, Laura Rassenti, Diana Krupnik, Susan Lerner, Ruth LaPushin, Lianchun Xiao, Xuelin Huang, Lillian Werner, Donna Neuberg, Hagop Kantarjian, Susan O'Brien, William G. Wierda, Michael J. Keating, Andreas Rosenwald, Jan A. Burger

Blood (2011) 117 (5): 1662–1669.

https://doi.org/10.1182/blood-2010-09-307249

Published: 2011

Includes: Supplemental data

Journal Articles

microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival

Blood (2010) 116 (6): 945–952.

https://doi.org/10.1182/blood-2010-01-263889

Published: 2010

Includes: Supplemental data

Journal Articles

Palonosetron (PALO) Given Daily for up to 5 Days Is Significantly Better Than Ondansetron (ONDA) in the Prevention of Delayed CINV in Patients (pts) with Acute Myelogenous Leukemia (AML).

Gloria Mattiuzzi, MD, Jorge Cortes, MD, Deborah McCue, PhDP, B. Nebiyou Bekele, PhD, Lianchun Xiao, Gautam Borthakur, MD, Hagop Kantarjian, MD

Blood (2009) 114 (22): 993.

https://doi.org/10.1182/blood.V114.22.993.993

Published: 2009

Journal Articles

Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome–negative acute lymphocytic leukemia

Hui Yang, Tapan Kadia, Lianchun Xiao, Carlos E. Bueso-Ramos, Koyu Hoshino, Deborah Ann Thomas, Susan O'Brien, Elias Jabbour, Sherry Pierce, Gary L. Rosner, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2009) 113 (9): 1892–1898.

https://doi.org/10.1182/blood-2008-02-141002

Published: 2009

Journal Articles

Outcome and Predictive Factors of Patients (pts) with Hematologic Malignancies (HM) Admitted to the Intensive Care Unit (ICU)

Gloria Mattiuzzi, MD, Jorge Cortes, Lianchun Xiao, Sherry Pierce, Hagop Kantarjian

Blood (2008) 112 (11): 3986.

https://doi.org/10.1182/blood.V112.11.3986.3986

Published: 2008

Journal Articles

Stem Cell Transplantation in Remission Improves Survival in Acute Myelogenous Leukemia Associated with FLT3 Mutations

Gautam Borthakur, MD, Marcos de Lima, MD, Hagop Kantarjian, MD, Lianchun Xiao, MS, Leandro de Padua Silva, MD, Guillermo Garcia-Manero, MD, Sergio Giralt, MD, Farhad Ravandi-Kashani, MD, Sherry Pierce, Richard Champlin, MD

Blood (2008) 112 (11): 3302.

https://doi.org/10.1182/blood.V112.11.3302.3302

Published: 2008

Journal Articles

Overexpression of CXCR4 in Acute Myeloid Leukemia Predicts Adverse Overall and Progression-Free Survival Independently of FLT3 Gene Mutation.

Sergej Konoplev, MD, PhD, George Z. Rassidakis, MD,PhD, Elihu H. Estey, MD, Hagop M. Kantarjian, MD, Xuelin Huang, PhD, Lianchun Xiao, Michael Andreeff, MD,PhD, Marina Konopleva, MD,PhD, L. Jeffrey Medeiros, MD

Blood (2006) 108 (11): 1890.

https://doi.org/10.1182/blood.V108.11.1890.1890

Published: 2006

NARROW

A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated with Upregulation of HOX Genes: Trial in Progress

A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

Azacitidine, Venetoclax and Allogeneic NK Cells in Newly Diagnosed Acute Myeloid Leukemia (ADVENT-AML): An Investigator-Initiated Multicenter Phase Ib Trial

Characteristics and Outcomes of Adult Patients with Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Single-Center, Prospective Analysis

Improved Survival for MDS/CMML Patients Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC Alone Vs. DAC +/- Carboplatin or ATO

Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML)

Superior Response Rates for Patients with Myeloid Malignancies Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC +/- Carboplatin or ATO

A Phase I/II Study Of Hyper-CVAD Plus Everolimus In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia

Serum CCL3 and CCL4 Levels Function As Novel Prognostic Markers in Diffuse Large B Cell Lymphoma.

Coagulation Profile As Prognostic Indicator in Acute Myeloid Leukemia,

CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia

microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival

Palonosetron (PALO) Given Daily for up to 5 Days Is Significantly Better Than Ondansetron (ONDA) in the Prevention of Delayed CINV in Patients (pts) with Acute Myelogenous Leukemia (AML).

Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome–negative acute lymphocytic leukemia

Outcome and Predictive Factors of Patients (pts) with Hematologic Malignancies (HM) Admitted to the Intensive Care Unit (ICU)

Stem Cell Transplantation in Remission Improves Survival in Acute Myelogenous Leukemia Associated with FLT3 Mutations

Overexpression of CXCR4 in Acute Myeloid Leukemia Predicts Adverse Overall and Progression-Free Survival Independently of FLT3 Gene Mutation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only